These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
205 related articles for article (PubMed ID: 14709942)
41. Obsessive-compulsive disorder: a 3-year prospective follow-up study of patients treated with serotonin reuptake inhibitors OCD follow-up study. Catapano F; Perris F; Masella M; Rossano F; Cigliano M; Magliano L; Maj M J Psychiatr Res; 2006 Sep; 40(6):502-10. PubMed ID: 16904424 [TBL] [Abstract][Full Text] [Related]
42. Serotonin transporter promoter variants in autism: functional effects and relationship to platelet hyperserotonemia. Anderson GM; Gutknecht L; Cohen DJ; Brailly-Tabard S; Cohen JH; Ferrari P; Roubertoux PL; Tordjman S Mol Psychiatry; 2002; 7(8):831-6. PubMed ID: 12232775 [TBL] [Abstract][Full Text] [Related]
43. Metacognitive beliefs predict early response to pharmacological treatment in patients with obsessive-compulsive disorder. Park CI; Kim HW; Jeon S; Hwang EH; Kang JI; Kim SJ Psychopharmacology (Berl); 2020 Nov; 237(11):3489-3496. PubMed ID: 32748029 [TBL] [Abstract][Full Text] [Related]
44. Quetiapine addition to serotonin reuptake inhibitor treatment in patients with treatment-refractory obsessive-compulsive disorder: an open-label study. Denys D; van Megen H; Westenberg H J Clin Psychiatry; 2002 Aug; 63(8):700-3. PubMed ID: 12197450 [TBL] [Abstract][Full Text] [Related]
45. Effects of selective serotonin reuptake inhibitors on platelet serotonin parameters in major depressive disorder. Bakish D; Cavazzoni P; Chudzik J; Ravindran A; Hrdina PD Biol Psychiatry; 1997 Jan; 41(2):184-90. PubMed ID: 9018388 [TBL] [Abstract][Full Text] [Related]
46. Inhibition of norepinephrine uptake in patients with major depression treated with paroxetine. Gilmor ML; Owens MJ; Nemeroff CB Am J Psychiatry; 2002 Oct; 159(10):1702-10. PubMed ID: 12359676 [TBL] [Abstract][Full Text] [Related]
47. Inositol augmentation of serotonin reuptake inhibitors in treatment-refractory obsessive-compulsive disorder: an open trial. Seedat S; Stein DJ Int Clin Psychopharmacol; 1999 Nov; 14(6):353-6. PubMed ID: 10565802 [TBL] [Abstract][Full Text] [Related]
48. Decreased serotonin transporter binding in unaffected relatives of manic depressive patients. Leboyer M; Quintin P; Manivet P; Varoquaux O; Allilaire JF; Launay JM Biol Psychiatry; 1999 Dec; 46(12):1703-6. PubMed ID: 10624553 [TBL] [Abstract][Full Text] [Related]
49. Effects of long-term lithium treatment on monoaminergic functions in major depression. El Khoury A; Johnson L; Aberg-Wistedt A; Stain-Malmgren R Psychiatry Res; 2001 Dec; 105(1-2):33-44. PubMed ID: 11740973 [TBL] [Abstract][Full Text] [Related]
50. Increased inhibitory activity of protein kinase C on the serotonin transporter in OCD. Marazziti D; Masala I; Rossi A; Hollander E; Presta S; Giannaccini G; Mazzoni MR; Dell'Osso L; Lucacchini A; Cassano GB Neuropsychobiology; 2000; 41(4):171-7. PubMed ID: 10828725 [TBL] [Abstract][Full Text] [Related]
51. Binding of [(3)H]lysergic acid diethylamide to serotonin 5-HT(2A) receptors and of [(3)H]paroxetine to serotonin uptake sites in platelets from healthy children, adolescents and adults. Sigurdh J; Spigset O; Allard P; Mjörndal T; Hägglöf B Neuropsychobiology; 1999 Nov; 40(4):183-7. PubMed ID: 10559700 [TBL] [Abstract][Full Text] [Related]
52. Can serotonin transporter genotype predict serotonergic function, chronicity, and severity of drinking? Johnson BA; Javors MA; Roache JD; Seneviratne C; Bergeson SE; Ait-Daoud N; Dawes MA; Ma JZ Prog Neuropsychopharmacol Biol Psychiatry; 2008 Jan; 32(1):209-16. PubMed ID: 17950969 [TBL] [Abstract][Full Text] [Related]
53. Higher serotonin transporter availability in early-onset obsessive-compulsive disorder patients undergoing escitalopram treatment: A [ Lee J; Kim BH; Kim E; Howes OD; Cho KIK; Yoon YB; Kwon JS Hum Psychopharmacol; 2018 Jan; 33(1):. PubMed ID: 29210107 [TBL] [Abstract][Full Text] [Related]
54. Association of SLC1A1 gene polymorphism with obsessive compulsive disorder in a sample from southern India. Shukla T; Nadella RK; Taj M J RJ; Ganesh S; Nestadt G; Purushottam M; Jain S; Reddy YCJ; Viswanath B Exp Clin Psychopharmacol; 2020 Dec; 28(6):617-621. PubMed ID: 31985241 [TBL] [Abstract][Full Text] [Related]
55. Decreased inhibitory activity of PKC in OCD patients after six months of treatment. Marazziti D; Dell'Osso L; Masala I; Baroni S; Presta S; Giannaccini G; Di Nasso E; Mungai F; Lucacchini A; Cassano GB Psychoneuroendocrinology; 2002 Oct; 27(7):769-76. PubMed ID: 12183213 [TBL] [Abstract][Full Text] [Related]
56. Association analysis of the catechol-o-methyltransferase (COMT), serotonin transporter (5-HTT) and serotonin 2A receptor (5HT2A) gene polymorphisms with obsessive-compulsive disorder. Meira-Lima I; Shavitt RG; Miguita K; Ikenaga E; Miguel EC; Vallada H Genes Brain Behav; 2004 Apr; 3(2):75-9. PubMed ID: 15005715 [TBL] [Abstract][Full Text] [Related]
60. Circannual variations in the binding of [3H]lysergic acid diethylamide to serotonin2A receptors and of [3H]paroxetine to serotonin uptake sites in platelets from healthy volunteers. Spigset O; Allard P; Mjörndal T Biol Psychiatry; 1998 May; 43(10):774-80. PubMed ID: 9606533 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]